The Washington Post (10/3, McGinley) reports in “To Your Health” that “breast cancer death rates declined” nearly “40 percent between 1989 and 2015, averting 322,600 deaths, the American Cancer Society reported” yesterday in CA: A Cancer Journal for Clinicians. The study indicated “breast cancer death rates increased by 0.4 percent per year from 1975 to 1989.” However, “after that, mortality rates decreased rapidly, for a 39 percent drop overall through 2015.”
TIME (10/3, Park) reports, “In some states, the death rates from breast cancer among white women and black women are equalizing, suggesting that access to screening and treatments are more evenly distributed in those parts of the” US. However, “the data still show that black women have the highest death rates from breast cancer nationally.”
Meanwhile, HealthDay (10/3, Dallas) reports, “The median age for breast cancer deaths is 68, but black patients died younger – at 62, on average.” Also covering the story are Medscape (10/3, Nelson) and Healio (10/3, Leiser).
Aunt Minnie (10/3, Kim) reports that there are “substantial differences around the world in the amount of radiation dose being used for CT scans,” according to a study published online in the American Journal of Roentgenology. Swiss researchers used radiation dose-tracking software to study the amounts in select North American and European medical institutions and found that “CT dose levels measured at California hospitals and from facilities reporting to the American College of Radiology (ACR) Dose Index Registry (DIR) were up to 240% higher than the dose used at their facility, University Hospital Basel.” The piece concludes, “the inconsistency in CT radiation dose used at local neighboring facilities and the wide-ranging differences among distinct registries suggest the need for dose optimization, according to the authors.”
DOT Med News (9/26, Fischer) reports that scientists “have created a new MR contrast agent that can locate and differentiate between aggressive and slow-growing, low-risk types of breast cancer at early stages.” According to DOT Med News, “The gadolinium-based agent lights up cancer biomarkers during scans, overcoming the low sensitivity of MR for imaging markers, and produces signals with different shades ofbrightness that contrast aggressive from slow-growing, low-risk types of cancer.” The research was published in Nature Communications.